NASDAQ: OCS - Oculis Holding AG

Lønnsomhet i seks måneder: +44.65%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Oculis Holding AG

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.

flere detaljer
The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2023-03-02
ISIN CH1242303498
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://oculis.com
Цена ао 12.65
Prisendring per dag: -0.6444% (17.07)
Prisendring per uke: -0.1178% (16.98)
Prisendring per måned: +4.95% (16.16)
Prisendring over 3 måneder: +37.76% (12.3116)
Prisendring over seks måneder: +44.65% (11.725)
Prisendring per år: +51.02% (11.23)
Prisendring over 3 år: +74.67% (9.71)
Prisendring over 5 år: 0% (16.96)
Prisendring over 10 år: 0% (16.96)
Prisendring siden begynnelsen av året: +14.91% (14.76)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 317.87 1
P/BV 2.99 6
P/E 0 0
EV/EBITDA -5.31 0
Total: 3.5

Effektivitet

Navn Betydning Karakter
ROA, % -77.66 0
ROE, % -94.74 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0132 10
Total: 9.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -11.08 0
Lønnsomhet Ebitda, % 277.99 10
Lønnsomhet EPS, % 478.83 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Pivotal bioVenture Partners Investment Advisor, LLC 1888788 4.66
Abrdn PLC 1452741 3.59
Nan Fung Group Holdings Limited 518933 1.28
Compagnie Lombard Odier SCmA 95750 0.24
Bank of America Corporation 16926 0.04
Searle & Co. 10000 0.02
Dupont Capital Management Corp 4 0



Veileder Stillingstittel Betaling Fødselsår
Dr. Riad Sherif M.B.A., M.D. CEO & Director N/A 1968 (57 år)
Ms. Sylvia Cheung Chief Financial Officer N/A 1975 (50 år)
Mr. Páll Ragnar Jóhannesson Chief Business Officer N/A 1982 (43 år)
Ms. Rebecca Weil Chief Commercial Officer N/A
Dr. Ramin Tadayoni M.D., Ph.D. Chief Scientific Officer N/A
Ms. Virginia R. Dean Chief Human Resources Officer N/A 1967 (58 år)
Dr. Bastian Dehmel M.D. Chief Development Officer N/A 1971 (54 år)
Dr. Snehal Shah Pharm.D. President of Research & Development N/A
Dr. Sharon Klier M.D., M.P.H. Chief Development Officer

Adresse: Switzerland, Zug, Bahnhofstrasse 7 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://oculis.com